里德-斯特恩伯格细胞
斯达
医学
淋巴瘤
癌症研究
病理
生物标志物
肿瘤科
经典霍奇金淋巴瘤
霍奇金淋巴瘤
内科学
生物
霍奇金淋巴瘤
细胞凋亡
生物化学
车站3
作者
Ahmad Zargari,Katherine D. Cummins,Patrick Hosking,Alan Pham,Eliza A. Hawkes,Stephen B. Ting
出处
期刊:Pathology
[Elsevier BV]
日期:2023-04-19
卷期号:55 (5): 650-655
被引量:1
标识
DOI:10.1016/j.pathol.2023.02.007
摘要
Classic Hodgkin lymphoma (cHL) prognostication primarily relies on clinical and radiological factors. Despite this, a subset of patients still progress. Immunohistochemistry (IHC) based biomarkers on diagnostic tissue have not been routinely used for prognostication. A multicentre retrospective analysis identified 62 patients with cHL. IHC on diagnostic tissues was used to stain Reed-Sternberg cells (RS) cells for STAT1, pSTAT3, p53 and tumour microenvironment for CD68 and PD-1. IHC stains were scored by anatomical pathologists blinded to patients and their outcomes and correlated with survival. Strong intensity of STAT1 and pSTAT3 staining correlated with improved overall survival (OS), with hazard ratios (HR) of 0.21 [95% confidence interval (CI) 0.06-0.76] and 0.22 (95% CI 0.06-0.84), respectively. Similarly, the median OS for weak versus strong STAT1 or pSTAT3 staining was 8.8 years versus not reached. Other IHC stains did not correlate with prognosis. In this cohort of cHL patients, downregulation of immunohistochemical STAT1 or pSTAT3 in RS cells is associated with inferior OS, suggesting STAT transcription within the pathognomonic RS cells may have tumour suppressor function and may be a potential biomarker for cHL prognosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI